**Supplementary table 2: Prognosis according to different clinical, radiological & ApoE characteristics.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Characteristics** | **Total n= 28 No.(%)** | **Good outcome n=13, No.(%)** | **Poor outcome n=15, No.(%)** | **p value** |
| Age, years (mean) | 72 | 71 | 73 | 0.50 |
| Follow-up, months (median) | 18.5 | 21 | 13 | 0.91 |
| **CMBs Mean (range)** | **240** | **312** | **168** | **0.02\*** |
| cSS No.(%) |  |  |  | 0.79 |
| none | 14 (50) | 8 (62) | 6 (40) |  |
| focal | 8 (29) | 3 (23) | 5 (33) |  |
| disseminated | 6 (21) | 2 (15) | 4 (27) |  |
| Treatment |  |  |  | 1 |
| yes | 22 (79) | 10 (77) | 12 (80) |  |
| no | 6 (21) | 3 (23) | 3 (20) |  |
| Type of treatment:  |  |  |  | 0.88 |
| no | 6 (21) | 3 (23) | 3 (20) |  |
| steroid | 16 (58) | 8 (62) | 8 (53) |  |
| immunosuppressant | 6 (21) | 2 (15) | 4 (27) |  |
| ApoE = 20 No.(%) |  |  |  |  |
|  E2≥1 allele | 2 (10) | 0 | 2 | 0.18 |
|  **E4≥ 1 allele** | **14 (70)** | **10** | **4** | **0.048\*** |
| **Initial evolution favorable** | **23 (82)** | **13 (100)** | **10 (67)** | **0.028\*** |

\* p<0.05